SCHEMBL2154104

SCHEMBL2154104

Fc1ccccc1Sc1ccccc1CNC1=NCCN1

nearest known ligand 0.97

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.97
GAA P10253 1/20 0.97
APOBEC3A P31941 1/20 0.97
CTDSP1 Q9GZU7 1/20 0.97
APOBEC3G Q9HC16 1/20 0.97
SMN1; SMN2 Q16637 1/20 0.69
NLRP3 Q96P20 1/20 0.69
PTGIR P43119 1/20 0.44
WDR5 P61964 11/20 0.42
ADRA1D P25100 2/20 0.40
ADRA1A P35348 2/20 0.40
ADRA1B P35368 2/20 0.40
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2161463 0.85 LMNA (0.98) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL560405 0.85 LMNA (0.71) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL2153939 0.82 SMN1; SMN2 (0.98) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL13063071 0.80 LMNA (0.64) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL10022889 0.77 LMNA (0.62) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL561403 0.77 LMNA (0.62) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL12463008 0.76 LMNA (0.66) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL8146510 0.75 LMNA (0.58) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
Iodide SCHEMBL3168283 0.74 LMNA (0.60) LMNAGAAAPOBEC3ACTDSP1APOBEC3G
SCHEMBL560777 0.74 LMNA (0.56) LMNAGAAAPOBEC3ACTDSP1APOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513064-B1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS UNIV LEUVEN KATH (BE) 2018-07-04 EP claimed
US-20130029981-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2013-01-31 US claimed
EP-2513064-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2012-10-24 EP claimed
WO-2011080132-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2011-07-07 WO claimed
EP-2513064-B1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS UNIV LEUVEN KATH (BE) 2018-07-04 EP disclosed
US-8906915-B2 Compounds, compositions, and methods for controlling biofilms KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2014-12-09 US disclosed
US-8906915-B2 Compounds, compositions, and methods for controlling biofilms KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2014-12-09 US disclosed
US-20130029981-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2013-01-31 US disclosed
US-20130029981-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2013-01-31 US disclosed
WO-2011080132-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029981-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS AZI2, NOD1, AADAC LMNA 4394/4885GAA 1825/4885APOBEC3A 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.